<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956744</url>
  </required_header>
  <id_info>
    <org_study_id>IMS001-01</org_study_id>
    <nct_id>NCT04956744</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis</brief_title>
  <official_title>A Phase 1, Dose-Escalating, Open-label Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Single Dose of IV IMS001 in Subjects With Multiple Sclerosis and Treatment Failure to Prior Disease Modifying Treatments (DMTs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImStem Biotechnology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImStem Biotechnology</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis&#xD;
      who experience inadequate response and/or intolerability to disease modifying treatments.&#xD;
      IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the&#xD;
      potential to modulate disease course.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Day 1 to Month 60</time_frame>
    <description>Frequency of treatment-emergent adverse events (TEAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Day 1 to Month 60</time_frame>
    <description>Clinically significant laboratory abnormalities.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1 and at Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMS001</intervention_name>
    <description>IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Optional Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provides signed and dated informed consent in accordance with local regulations.&#xD;
&#xD;
          -  18 to 65 years of age.&#xD;
&#xD;
          -  Diagnosis of MS.&#xD;
&#xD;
          -  Has had an inadequate response DMTs.&#xD;
&#xD;
          -  EDSS within protocol parameters.&#xD;
&#xD;
          -  Able and willing to undergo MRIs.&#xD;
&#xD;
          -  Must be clinically stable for 1 month prior to Day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known or suspected hypersensitivity to human serum albumin, diphenhydramine,&#xD;
             acetaminophen, methylprednisolone, or any of the components of IMS001.&#xD;
&#xD;
          -  Has history of excluded medications, per protocol, prior to Day 1.&#xD;
&#xD;
          -  Has a history of neoplastic disease except for basal cell carcinoma, non-metastatic&#xD;
             squamous cell carcinoma of the skin that has been excised with clean margins, or&#xD;
             adequately treated in-situ carcinoma of the cervix.&#xD;
&#xD;
          -  Prior history of any other autoimmune disease, myelodysplasia, or hematologic disease.&#xD;
&#xD;
          -  Prior treatment with any allogeneic cell therapy or tissue transplant.&#xD;
&#xD;
          -  Prior history of smoking equivalent to ˃20 cumulative pack years of cigarettes.&#xD;
&#xD;
          -  Recent clinically significant infection during the Screening Phase.&#xD;
&#xD;
          -  Has any medical or psychiatric condition that would impact outcome or participation in&#xD;
             the study.&#xD;
&#xD;
          -  Has clinically significant abnormal findings on the electrocardiogram (ECG) during the&#xD;
             Screening Phase.&#xD;
&#xD;
          -  Has known or documented human immunodeficiency virus (HIV) infection or active&#xD;
             Hepatitis B, or C.&#xD;
&#xD;
          -  Has an elevated liver function test abnormality during the Screening Phase.&#xD;
&#xD;
          -  Has abnormalities of blood count during the Screening Phase.&#xD;
&#xD;
          -  Has laboratory abnormalities of renal function during the Screening Phase.&#xD;
&#xD;
          -  Has other clinically significant laboratory abnormalities during Screening Phase.&#xD;
&#xD;
          -  Body weight ≥120 kg.&#xD;
&#xD;
          -  Women pregnant, breast feeding, or planning to become pregnant during the study.&#xD;
&#xD;
          -  Is unavailable for the duration of the trial, is likely to be noncompliant with the&#xD;
             protocol, or is generally felt to be unsuitable by the principal investigator.&#xD;
&#xD;
          -  Current or recent participation in any other clinical or device trials within 3 months&#xD;
             prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImStem Biotechnology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Kim, MD</last_name>
    <phone>860-281-7836</phone>
    <email>richard.kim@imstem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain MS Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.imstem.com/</url>
    <description>Imstem Biotechnology</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

